Brain Scientific Inc. (BRSF) Eyes Plans for 2021 and Beyond

May 6, 2021 09:47:01
  • Commercial application of NeuroEEG and NeuroCap growing across ICUs, acute inpatient care and other emergency care in U.S.
  • BRSF plans to launch devices in Canada
  • Company expands footprint, plans patent applications in Latin America, Europe

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has unveiled the outlook for 2021. Brain Scientific continues to make strides within neurology by revolutionizing the brain diagnostic market with its groundbreaking technology. The company recently announced that its R&D efforts surged in 2020 with an investment of $275,926, which marks a 266% increase over 2019’s total of $103,616 (

Despite a challenging year due to the pandemic, Brain Scientific reached significant milestones in 2020. A limited-scope commercial application of the NeuroEEG(TM) and NeuroCap(TM) is in progress in the United States, expected to be followed by the Canadian market. The initial entry market is identified as ICUs, acute inpatient care and other emergency facilities in the United States.

As 2020 drew to a close, Brain Scientific announced that its NeuroCap would become available to the pediatric market in the United States. The child-size NeuroCap headset helps overcome the common challenges medical professionals face when conducting electroencephalograms (“EEG”) in pediatrics by bringing comfort, speed and reliability to the brain testing of children (

At the end of last year, the company also filed a patent application for its new long-term monitoring EEG cap. It is a new flexible, full-head EEG cap developed as a response to the market demand for disposable EEG solution for prolonged EEG recordings (12 hours and longer). (

Brain Scientific is determined to bring its cutting-edge technology to the world and expand its footprint in the international landscape. Last year, the company established a wholly owned subsidiary in Russia and Europe (Poland) for product distribution and certification, and BRSF appears to have even bigger plans for the future.

Within the next 24 months, the company expects to scale production in the United States, expand into the EU market and file international patent applications in Latin America, Europe and more. Future plans also include the introduction of a BRSF long-term monitoring cap and the addition of long-term monitoring, 24-channel EEG to its proprietary lineup of diagnostic devices.

The third phase of development scheduled for 2021–2022 is also expected to be centered around the use of AI-powered data analysis to bring efficiency, consistency and accuracy to modern neurology diagnostics. This segment is intended to include the launch of data-storage capabilities for normalized data brain scans and the further development of the company’s planned AI neuro net while advancing application for minimally invasive graphene electrodes connected to the micro-EEG. At the forefront of neurology device technology, Brain Scientific appears poised to transform the neurology landscape and establish a new innovative norm for clinicians.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.